Literature DB >> 2432048

A unique epitope on the CD2 molecule defined by the monoclonal antibody 9-1: epitope-specific modulation of the E-rosette receptor and effects on T-cell functions.

A Bernard, R W Knowles, K Naito, B Dupont, B Raynal, H C Tran, L Boumsell.   

Abstract

Monoclonal antibody (MoAb) 9-1 shows unique binding properties to CD2 resulting in peculiar epitope specific changes. 9-1 shows competitive binding with MoAb to D66 epitope, and gives a similar staining pattern with T-cell populations, at a low density on resting T cells, and high density on thymocytes and activated T cells. However, 9-1 has the opposite effect on anti-D66 MoAbs on rosette formation, namely, 9-1 increases the stability of rosettes, but 9-1 plus anti-mouse Ig bound to T-cell surface blocks rosettes. 9-1 plus anti-mouse Ig, like anti-D66 MoAbs, induces further appearance of D66 and 9-1 epitopes but, contrary to anti-D66, induces appearance of T11(3) epitopes. Thus, binding 9-1 results in unique "epitope-specific modulation" events that are not solely artificial, but appear to mimic events naturally occurring during T-cell differentiation/activation. The effects of binding 9-1 on T-cell functions also display peculiarities. 9-1, like anti-D66 MoAbs, activates T cells when added in combination with anti-9.6/T11(1) MoAbs but not with anti-T11(3). To obtain full activation, monocytes are required; however, adding 9-1 alone do not inhibit specific T-cell cytotoxicity contrary to anti-D66 or anti-9.6/T11(1), although 9-1 inhibits NK activity of peripheral cells. Given the apparent complexities of the functions exerted by CD2, these data show that definite conformational changes or reorientation, which would be naturally produced by soluble and/or cell surface ligand(s), would be key events in determining how CD2 will influence T-cell functions.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2432048     DOI: 10.1016/0198-8859(86)90299-5

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  8 in total

1.  T-cell stimulation through the T-cell receptor/CD3 complex regulates CD2 lateral mobility by a calcium/calmodulin-dependent mechanism.

Authors:  S Q Liu; D E Golan
Journal:  Biophys J       Date:  1999-03       Impact factor: 4.033

Review 2.  The role of leukocyte adhesion molecules in cellular interactions: implications for the pathogenesis of inflammatory synovitis.

Authors:  B F Haynes; L P Hale; S M Denning; P T Le; K H Singer
Journal:  Springer Semin Immunopathol       Date:  1989

3.  Studies on the monocyte dependence of T-cell proliferation induced by monoclonal antibodies directed against regions I and II of the CD2 antigen.

Authors:  R van Lier; E Bloemena; M Brouwer; J Van Heijst; S Weinreich; L Aarden
Journal:  Immunology       Date:  1989-07       Impact factor: 7.397

4.  A distinct cytoplasmic domain of CD2 regulates ligand avidity and T-cell responsiveness to antigen.

Authors:  W C Hahn; Y Rosenstein; V Calvo; S J Burakoff; B E Bierer
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-01       Impact factor: 11.205

5.  Intracellular mediators regulate CD2 lateral diffusion and cytoplasmic Ca2+ mobilization upon CD2-mediated T cell activation.

Authors:  S J Liu; W C Hahn; B E Bierer; D E Golan
Journal:  Biophys J       Date:  1995-02       Impact factor: 4.033

6.  Correlation of CD2 binding and functional properties of multimeric and monomeric lymphocyte function-associated antigen 3.

Authors:  M L Dustin; D Olive; T A Springer
Journal:  J Exp Med       Date:  1989-02-01       Impact factor: 14.307

7.  Separable portions of the CD2 cytoplasmic domain involved in signaling and ligand avidity regulation.

Authors:  W C Hahn; B E Bierer
Journal:  J Exp Med       Date:  1993-11-01       Impact factor: 14.307

8.  Early events in human T cell ontogeny. Phenotypic characterization and immunohistologic localization of T cell precursors in early human fetal tissues.

Authors:  B F Haynes; M E Martin; H H Kay; J Kurtzberg
Journal:  J Exp Med       Date:  1988-09-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.